Previous 10 | Next 10 |
New Data Presented on the Neovasc Reducer™ in Patients With Microvascular Disease VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - September 20, 2022 - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX : NVCN ) announced positive clinica...
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in He...
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 15, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") development of new codes for the di...
VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - September 08, 2022 - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX : NVCN ) today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 confe...
VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - August 30, 2022 - Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright 24 th Annual Global Investment Conference to be held ...
Neovasc Inc. (NVCN) Q2 2022 Results Conference Call August 11, 2022 04:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Fred Colen - President and Chief Executive Officer Chris Clark - Chief Financial Officer Conference Call Participants ...
Neovasc press release ( NASDAQ: NVCN ): Q2 GAAP EPS of -$3.29 misses by $0.93 . Revenue of $0.82M (+30.2% Y/Y) beats by $0.13M . For further details see: Neovasc GAAP EPS of -$3.29 misses by $0.93, revenue of $0.82M beats by $0.13M
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Generated revenues of $818,000, ...
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Ch...
Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 26, 2022) - Neovasc , Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the United States Food and Drug Administration ("FDA") has approved a protocol supplement to the COSIRA-II Investig...
News, Short Squeeze, Breakout and More Instantly...
Neovasc Inc. (NASDAQ: NVCN) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.48% on the day to $29.23. Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. It...
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Hi...
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as d...